Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the maximum tolerated dose/recommended phase II dose of
the combination regimen of NK012 and 5-fluorouracil in patients with advanced solid tumors.